Breaking Finance News

A statement released earlier today by Evercore ISI about C R Bard Inc (NYSE:BCR) bumps the target price to $235.00

Evercore ISI upped the price target of C R Bard Inc (NYSE:BCR) to $235, reporting a possible upside of 0.08%,

On 5/24/2016, Barclays Capital released a statement for C R Bard Inc(NYSE:BCR) upped the target price from $212.00 to $224.00. At the time, this suggested an upside of 0.01%.

Displaying a price of $216.91, C R Bard Inc (NYSE:BCR) traded 3.25% higher on the day. The last stock price close is up 3.45% relative to the 200-day moving average, compared to the S&P 500 Index which has fallen -0.01% over the date range. C R Bard Inc has registered a 50-day average of $219.98 and 200-day average of $216.50. 660,450 shares of BCR exchanged hands, up from ann average volume of 438,609

See Chart Below:

C R Bard Inc (NYSE:BCR)

With a total market value of $0.0, C R Bard Inc has a price-earnings of 52 with a 52 week low of $172.21 and a 52 week high of $239.43.

Also covering C R Bard Inc’s price target, a total of 14 firms have released a research note on the stock. The average target price is $226.21 with two analysts rating the stock a strong buy, four analysts rating the stock a buy, 14 analyts rating the stock a hold, 0 rating the company to underperform, and finally 0 firmsrating the stock as sell.

More About C R Bard Inc (NYSE:BCR)

C. R. Bard, Inc. (Bard) and its subsidiaries are engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company sells its products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities. It operates through the manufacturing and sale of medical devices segment. Its vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease (PVD), end-stage renal disease (ESRD) and heart arrhythmias. Its urology products include basic urology drainage products, fecal and urinary continence products, and urological specialty products and Targeted Temperature Management products. Its oncology products cover a range of devices used in the treatment and management of various cancers and other diseases and disorders. Its surgical specialty products include implanted grafts and fixation devices for hernia and soft tissue repairs.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *